Inma Rioja

Inma Rioja

Company: GlaxoSmithKline

Job title: Head of Immuno- Epigenetics and B cell Biology (Immunology Research Unit. GSK)


Drugging Transcription: Selective Targeting of BD1 & BD2 of the BET Proteins in Cancer & Immunoinflammation 1:50 pm

• Epigenetic modulators are providing the opportunity to characterise and understand immune responses in disease models. • GSK has identified highly potent and selective small molecule inhibitors of the first (BD1) and second (BD2) bromodomains of the BET reader proteins • BD1-selective inhibition phenocopies the effects of pan-BET inhibitors in cancer models and BD2-selective inhibitors…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.